Development of peptidic dopamine transporter inhibitors via aromatic modification-mediated conformational restriction

Journal of Medicinal Chemistry

Volumn 49, Issue 14, 2006, Pages 4048-4051

  Ding, Jinguo ^a,e   Shi, Jiahao ^a   Cui, Dafu ^a   Xu, Linfeng ^d   Duan, Shuhui ^c   Guo, Lihe ^a,d   Fei, Jian ^b,c  

^a INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

^b Shanghai Nan Fang Model Organism Research Center   (China)

^c Shanghai Jiao Tong University Affiliated Sixth People s Hospital   (China)

^d Shanghai Celstar Institute of Biotechnology   (China)

^e UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

4,4' BIPHENYLALANYLTYROSYLTHREONYLPROLYLTHREONYLGLYCINE; BENZATROPINE; DOPAMINE TRANSPORTER; DOPAMINE UPTAKE INHIBITOR; UNCLASSIFIED DRUG; VANOXERINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BEHAVIOR; CHEMICAL MODIFICATION; COCAINE DEPENDENCE; DRUG CONFORMATION; MOUSE; NONHUMAN; PROTEIN BINDING; PROTEIN CONFORMATION;

ANIMALS; BENZOIC ACIDS; BINDING SITES; BIPHENYL COMPOUNDS; CENTRAL NERVOUS SYSTEM STIMULANTS; CHO CELLS; COCAINE; CONDITIONING (PSYCHOLOGY); CRICETINAE; CRICETULUS; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; MICE; MOTOR ACTIVITY; NAPHTHALENES; OLIGOPEPTIDES; PROTEIN STRUCTURE, SECONDARY; RADIOLIGAND ASSAY; RATS; REWARD; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 33745842592     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0601654     Document Type: Article

References (30)

1. Ritz, M. C.; Lamb, R. J.; Goldberg, S. R.; Kuhar, M. J. Cocaine receptors on dopamine transporters are related to self-administration of cocaine. Science 1987, 237, 1219-1223.
2. Volkow, N. D.; Wang, G. J.; Fischman, M. W.; Foltin, R. W.; Fowler, J. S.; Abumrad, N. N.; Vitkun, S.; Logan, J.; Gatley, S. J.; Pappas, N.; Hitzemann, R.; Shea, C. E. Relationship between subjective effects of cocaine and dopamine transporter occupancy. Nature 1997, 386, 827-830.
3. Giros, B.; Jaber, M.; Jones, S. R.; Wightman, R. M.; Caron, M. G. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature 1996, 379, 606-612.
4. Torres, G. E.; Gainetdinov, R. R.; Caron, M. G. Plasma membrane monoamine transporters: structure, regulation and function. Nat. Rev. Neurosci. 2003, 4, 13-25.
5. Carroll, F. I.; Lewin, A. H.; Boja, J. W.; Kuhar, M. J. Cocaine receptor: biochemical characterization and structure-activity relationships of cocaine analogues at the dopamine transporter. J. Med. Chem. 1992, 35, 969-981.
6. Newman, A. H.; Allen, A. C.; Izenwasser, S.; Katz, J. L. Novel 3 alpha-(diphenylmethoxy)tropane analogues: potent dopamine uptake inhibitors without cocaine-like behavioral profiles. J. Med. Chem. 1994, 37, 2258-2261.
7. Rothman, R. B.; Glowa, J. R. A review of the effects of dopaminergic agents on humans, animals, and drug-seeking behavior, and its implications for medication development. Focus on GBR 12909. Mol. Neurobiol. 1995, 11, 1-19.
8. Gorelick, D. A.; Gardner, E. L.; Xi, Z. X. Agents in development for the management of cocaine abuse. Drugs 2004, 64, 1547-1573.
9. Koppel, G.; Dodds, C.; Houchins, B.; Hunden, D.; Johnson, D.; Owens, R.; Chaney, M.; Usdin, T.; Hoffman, B.; Brownstein, M. Use of peptide combinatorial libraries in drug design: the identification of a potent serotonin reuptake inhibitor derived from a tripeptide cassette library. Chem. Biol. 1995, 2, 483-487.
10. Rothman, R. B.; Baumann, M. H.; Dersch, C. M.; Appel, J.; Houghten, R. A. Discovery of novel peptidic dopamine transporter ligands by screening a positional scanning combinatorial hexapeptide library. Synapse 1999, 33, 239-246.
11. Liu, Z.; Wang, Y.; Zhao, W.; Ding, J.; Mei, Z.; Guo, L.; Cui, D.; Fei, J. Peptide derived from insulin with regulatory activity of dopamine transporter. Neuropharmacology 2001, 41, 464-471.
12. Lifson, J. D.; Hwang, K. M.; Nara, P. L.; Fraser, B.; Padgett, M.; Dunlop, N. M.; Eiden, L. E. Synthetic CD4 peptide derivatives that inhibit HIV infection and cytopathicity. Science 1988, 241, 712-716.
13. Gacel, G.; Dauge, V.; Breuze, P.; Delay-Goyet, P.; Roques, B. P. Development of conformationally constrained linear peptides exhibiting a high affinity and pronounced selectivity for delta opioid receptors. J. Med. Chem. 1988, 31, 1891-1897.
14. Zhang, X.; Piatier-Tonneau, D.; Auffray, C.; Murali, R.; Mahapatra, A.; Zhang, F.; Maier, C. C.; Saragovi, H.; Greene, M.I. Synthetic CD4 exocyclic peptides antagonize CD4 holoreceptor binding and T cell activation. Nat. Biotechnol. 1996, 14, 472-475.
15. Berezov, A.; Zhang, H. T.; Greene, M. I.; Murali, R. Disabling erbB receptors with rationally designed exocyclic mimetics of antibodies: structure-function analysis. J. Med. Chem. 2001, 44, 2565-2574.
16. Ahn, J. M.; Medeiros, M.; Trivedi, D.; Hruby, V. J. Development of potent truncated glucagon inhibitorinhibitors. J. Med. Chem. 2001, 44, 1372-1379.
17. Smith, D. D.; Saha, S.; Fang, G.; Schaffert, C.; Waugh, D. J.; Zeng, W.; Toth, G.; Hulce, M.; Abel, P. W. Modifications to the N-terminus but not the C-terminus of calcitonin gene-related peptide(8-37) produce inhibitorinhibitors with increased affinity. J. Med. Chem. 2003, 46, 2427-2435.
18. Aravinda, S.; Shamala, N.; Rajkishore, R.; Gopi, H. N.; Balaram, P. A crystalline beta-hairpin peptide nucleated by a type 1′ Aib-D-Ala beta-turn: evidence for cross-strand aromatic interactions. Angew. Chem., Int. Ed. 2002, 41, 3863-3865.
19. Sharpe, I. A.; Gehrmann, J.; Loughnan, M. L.; Thomas, L.; Adams, D. A.; Atkins, A.; Palant, E.; Craik, D. J.; Adams, D. J.; Alewood, P. F.; Lewis, R. J. Two new classes of conopeptides inhibit the alpha1-adrenoceptor and noradrenaline transporter. Nat. Neurosci. 2001, 4, 902-907.
20. Kieber-Emmons, T.; Murali, R.; Greene, M. I. Therapeutic peptides and peptidomimetics. Curr. Opin. Biotechnol. 1997, 8, 435-441.
21. DeGrado, W. F.; Summa, C. M.; Pavone, V.; Nastri, F.; Lombardi, A. De novo design and structural characterization of proteins and metalloproteins. Annu. Rev. Biochem. 1999, 68, 779-819.
22. Hruby, V. J. Designing peptide receptor agonists and inhibitorin- hibitors. Nat. Rev. Drug. Discovery 2002, 1, 847-858.
23. Vorel, S. R.; Ashby, C. R., Jr.; Paul, M.; Liu, X.; Hayes, R.; Hagan, J. J.; Middlemiss, D. N.; Stemp, G.; Gardner, E. L. Dopamine D3 receptor antagonism inhibits cocaine-seeking and cocaine-enhanced brain reward in rats. J. Neurosci. 2002, 22, 9595-9603.
24. Tzschentke, T. M. Reassessment of buprenorphine in conditioned place preference: temporal and pharmacological considerations. Psychopharmacology (Berl) 2004, 172, 58-67.
25. Tolliver, B. K.; Newman, A. H.; Katz, J. L.; Ho, L. B.; Fox, L. M.; Hsu, K., Jr.; Berger, S. P. Behavioral and neurochemical effects of the dopamine transporter ligand 4-chlorobenztropine alone and in combination with cocaine in vivo. J. Pharmacol. Exp. Ther. 1999, 289, 110-122.
26. Desai, R. I.; Kopajtic, T. A.; Koffarnus, M.; Newman, A. H.; Katz, J. L. Identification of a dopamine transporter ligand that blocks the stimulant effects of cocaine. J. Neurosci. 2005, 25, 1889-1893.
27. Rothman, R. B.; Mele, A.; Reid, A. A.; Akunne, H. C.; Greig, N.; Thurkauf, A.; de Costa, B. R.; Rice, K. C.; Pert, A. GBR12909 antagonizes the ability of cocaine to elevate extracellular levels of dopamine. Pharmacol. Biochem. Behav. 1991, 40, 387-397.
28. Carroll, F. I. 2002 Medicinal Chemistry Division Award address: monoamine transporters and opioid receptors. Targets for addiction therapy. J. Med. Chem. 2003, 46, 1775-1794.
29. Calcagnetti, D. J.; Keck, B. J.; Quatrella, L. A.; Schlechter, M. D. Blockade of cocaine-induced conditioned place preference: relevance to cocaine abuse therapeutics. Life Sci. 1995, 56, 475-483.
30. McGeehan, A. J.; Olive, M. F. The mGluR5 antagoinst MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse. Synapse 2003, 47, 240-242.